An advisory board recommended Wednesday that Arkansas’s Medicaid program eliminate restrictions on the use of an expensive cystic fibrosis drug made by Vertex Pharmaceuticals Inc. that are the subject of a legal battle in federal court. . Members of the state’s Drug Utilization Review Board, which is made up of Arkansas doctors and pharmacists, recommended that the state adopt a revised set of criteria for prescribing the drug, called Kalydeco, that wouldn’t require that patients seeking the drug first prove their health worsened...
  